App-Quantinova.ai

INFECTION AS A COMORBIDITY IN A COHORT OF RHEUMATOID ARTHRITIS PATIENTS FROM CLINICAL IMMUNOLOGY UNIT CENTRO HOSPITALAR DO PORTO

R.F. Alves - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

CURRENT MANAGEMENT PATTERNS OF SYNTHETIC DMARDS FOR RHEUMATOID ARTHRITIS IN THE CLINICAL PRACTICE SETTING: SAR-FAME STUDY

B. Hernandez Cruz - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

RITUXIMAB ASSOCIATED LATE ONSET NEUTROPAENIA: SAFETY OF RETREATMENT RITUXIMAB THERAPY IN 900 PATIENTS

J.F. Ferreira - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Rheumatoid arthritis

Hydroxychloroquine

BIOLOGICS IN MONOTHERAPY IN RHEUMATOID ARTHRITIS: A MULTICENTRIC RESTROSPECTIVE STUDY OF 109 PATIENTS

N. Rahal - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Rheumatoid arthritis

Hydroxychloroquine

NON-ADHERENCE TO DMARDS WILL SIGNIFICANTLY INFLUENCE THE FIRST-YEAR OUTCOME OF RHEUMATOID ARTHRITIS

A. Pasma - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Inflammatory Arthritis

Hydroxychloroquine

SERUM SURVIVIN PREDICTS TREATMENT RESPONSE IN ACTIVE RHEUMATOID ARTHRITIS

A. Levitsky - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

IMPACT OF NEGLECTING INTRA-ARTICULAR GLUCOCORTICOID-INJECTIONS IN REMISSION TARGETED TREATMENT OF EARLY RHEUMATOID ARTHRITIS

L. Kuusalo - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

PREDICTIVE FACTORS OF RADIOLOGICAL PROGRESSION AFTER TWO YEARS OF REMISSION STEERED TREATMENT IN EARLY ARTHRITIS PATIENTS

G. Akdemir - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Rheumatoid arthritis

Hydroxychloroquine

ONE-YEAR TREATMENT PATTERNS AND HEALTHCARE RESOURCE USE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS NEWLY INITIATING TREATMENT WITH BIOLOGIC DMARDS

J. Harnett - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

A DYNAMIC OF THE MULTI-BIOMARKER DISEASE ACTIVITY SCORE IN METHOTREXATE INCOMPLETE RESPONDERS IS PREDICTIVE FOR CLINICAL RESPONSE TO NON-BIOLOGICAL OR BIOLOGICAL THERAPY IN EARLY RA

K. Hambardzumyan - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

CERTOLIZUMAB PEGOL EXPOSURE IN RHEUMATOID ARTHRITIS PREGNANCIES: A CASE SERIES

M. Meroni - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

OUTCOMES OF SYSTEMIC JUVENILE ARTHRITIS (STIL-S DISEASE) IN ADULTS

N. Muravieva - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

EOSINOPHILIC FASCIITIS (SHULMA-S DISEASE): STUDY OF 70 CASES

W.A. Sifuentes Giraldo - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Eosinophilic fasciitis

Hydroxychloroquine

CAN IMMUNOSUPPRESSIVE DRUG TREATMENT REDUCE MORTALITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A PROPENSITY SCORE ANALYSIS OF A LONGITUDINAL COHORT OF 803 PATIENTS?

C.C. Mok - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

LONG TERM OUTCOME OF PRIMARY ANTIPHOSPHOLIPID SYNDROME PATIENTS: A MULTICENTER STUDY

M. Taraborelli - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

INFECTION AS A COMORBIDITY IN A COHORT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS FROM CLINICAL IMMUNOLOGY UNIT CENTRO HOSPITALAR DO PORTO

R.F. Alves - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

APPLICATION OF NEW EULAR DEFINITIONS OF REMISSION IN SLE: DURABLE ONE-YEAR REMISSION IS RARE

T.R. Fischer - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

DISEASE DAMAGE IS ASSOCIATED WITH INCREASED AORTIC STIFFNESS IN SYSTEMIC LUPUS ERYTHEMATOSUS: A CROSS-SECTIONAL STUDY

E. Bartoloni - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

CAN SPECKLE TRACKING ECHOCARDIOGRAPHY DECTECT LEFT SUBCLINAL VENTRICULAR DYSFUNCTION IN PATIENTS WITH PRIMARY SJOGREN SYNDROME?

F. Atzeni - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

Hydroxychloroquine

LONG-TERM OUTCOME OF SLE PATIENTS WITH JOINT ULTRASOUND ABNORMALITIES ASSOCIATED TO HAND INFLAMMATORY ARTHRALGIA

T.C. Salman Monte - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

Filters

1151 Abstracts